Mylan and Pfizer said they have actually gotten approval from the Federal Trade Commission for their deal to combine Mylan with Pfizers off-patent drug organization, Upjohn..
In March, the companies said they d push back the merger until the second half of this year due to unanticipated hold-ups in getting regulatory approval triggered by the COVID-19 pandemic..
© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this material? View our policies by click on this link.
Mylan and Pfizer first announced their strategies for a merger in July 2019 and stated the new business would be a worldwide pharmaceutical huge producing both generic and brand-name drugs. They said the brand-new company will offer widely known branded drugs such as Mylan EpiPen and Pfizers Viagra and could produce as much as $20 billion each year..
The new combined organization will be called Viatris, and its launching is anticipated to be Nov. 16.
More articles on pharmacy: Ascension launches drug store services service Ascension RxVirginia pharmacist gets 2 years in jail for prescription drug schemeAstraZeneca, Pfizer start accelerated evaluation for COVID-19 vaccines in UK.
Maia Anderson –
Tuesday, November 3rd, 2020